Capoten and Relafen drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Capoten (captopril) and Relafen (nabumetone). Common drug interactions include hot flush among females and abdominal pain among males.

The phase IV clinical study analyzes what interactions people have when they take Capoten and Relafen. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Capoten?

Capoten has active ingredients of captopril. It is often used in high blood pressure. eHealthMe is studying from 2,954 Capoten users. Check the latest studies of Capoten.

What is Relafen?

Relafen has active ingredients of nabumetone. It is often used in arthritis. eHealthMe is studying from 6,243 Relafen users. Check the latest studies of Relafen.



On Jul, 21, 2026

11 people who take Capoten and Relafen together, and have interactions are studied.

Capoten and Relafen drug interactions.

What are the common drug interactions of Capoten and Relafen, by gender? *:

female:

  1. Hot flush (sudden feelings of heat)
  2. Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
  3. Pruritus (severe itching of the skin)
  4. Androgenetic alopecia (common form of hair loss)
  5. Anxiety
  6. Breast cancer female
  7. Breast mass
  8. Cerebral ischaemia (insufficient blood flow to the brain to meet metabolic demand)
  9. Depression
  10. Endometrial hyperplasia (enlargement of uterus wall)

male:

  1. Abdominal pain
  2. Alanine aminotransferase increased
  3. Blood bilirubin increased

What are the common drug interactions of Capoten and Relafen, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Bronchospasm (spasm of bronchial smooth muscle producing narrowing of the bronchi)
  2. Hyperglycaemia (high blood sugar)

50-59:

  1. Breast cancer
  2. Endometrial hypertrophy (enlargement of uterine wall from the increase in size of its cells)
  3. Fibrocystic breast disease (a condition causing breast pain, cysts, and noncancerous breast lumps, affects many women)
  4. Vaginal haemorrhage (vaginal bleeding)
  5. Asthenia (weakness)
  6. Balance disorder
  7. Bone pain
  8. Hot flush (sudden feelings of heat)
  9. Androgenetic alopecia (common form of hair loss)
  10. Anxiety

60+:

  1. Abdominal distension
  2. Abdominal pain
  3. Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
  4. Dermatitis exfoliative (widespread scaling of the skin, often with itching (pruritus), skin redness (erythroderma), and hair loss)
  5. Epidermal necrolysis (skin condition that is usually caused by a reaction to drugs)
  6. Escherichia infection (bacterial infection by escherichia coli)
  7. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  8. Hypotension (abnormally low blood pressure)
  9. Intestinal infarction (intestinal tissue death)
  10. Lung infiltration (a substance that normally includes fluid, inflammatory exudates or cells that fill a region of lung)

What are the existing conditions these people have? *

  1. Stress And Anxiety: 4 people, 36.36%
  2. Osteopenia (a condition where bone mineral density is lower than normal): 4 people, 36.36%
  3. Osteoarthritis (a joint disease caused by cartilage loss in a joint): 4 people, 36.36%
  4. Migraine (headache): 4 people, 36.36%
  5. Menopausal Symptoms: 4 people, 36.36%
  6. Joint Pain: 4 people, 36.36%
  7. Depression: 4 people, 36.36%
  8. Acarodermatitis (skin inflammation caused by mites (acarids)): 4 people, 36.36%
  9. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 9.09%
  10. Menstruation Irregular: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Capoten and Relafen?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Capoten and Relafen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Capoten:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Relafen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Capoten and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Relafen and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on captopril and nabumetone (the active ingredients of Capoten and Relafen, respectively), and Capoten and Relafen (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: